Quantcast

American Oriental Bioengineering Receives Approval for Sales of Two Traditional Chinese Medicines in Hong Kong

May 10, 2011

NEW YORK, May 10, 2011 /PRNewswire-Asia-FirstCall/ — American Oriental Bioengineering, Inc. (NYSE: AOB), (“the Company” or “AOBO”), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter (“OTC”) products, today announced that the Company’s Zhibai Dihuang Pill (“ZD Pill”) and Ciwujia Tablet (“CWJ Tablet”) have been approved for sale as traditional Chinese medicine (“TCM”) in Hong Kong by Chinese Medicine Council of Hong Kong, (“CMCHK”).

Guangxi Lingfeng Pharmaceutical, (“GLP”), a wholly owned subsidiary of AOBO, is the manufacturer of ZD Pill, which is formulated entirely with pure natural ingredients and herbs. The medicine is indicated for the treatment of hot flush, night sweat, dry mouth, sore throat, etc.

Harbin Three Happiness Bioengineering (“3H”), a wholly owned subsidiary of AOBO, is the manufacturer of CWJ Tablet, which is formulated entirely with pure natural ingredients and herbs. The medicine is indicated for the treatment of fatigue, poor appetite, back pain and knee pain, and insomnia.

Mr. Tony Liu, Chairman and CEO of AOBO, commented, “We are honored to receive the approval for sales of additional two TCMs in Hong Kong. These newly-approved ZD Pill and CWJ Tablet, together with our LWDH mini Ball approved in March, are among the very few TCM products which are manufactured in mainland China and approved for marketing and sales in Hong Kong.”

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company’s filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


    Contact:
    ICR, LLC
    Christine Duan or Ashley Ammon
    203-682-8200

SOURCE American Oriental Bioengineering, Inc.


Source: newswire



comments powered by Disqus